ରାନିବିଜୁମାବ

ରାନିବିଜୁମାବ
Monoclonal antibody
Type	Fab fragment
Source	Humanized (from mouse)
Target	VEGF-A
Clinical data
Trade names	Lucentis, Byooviz
Synonyms	ranibizumab-nuna
AHFS/Drugs.com	monograph
MedlinePlus	a607044
data	EU EMA: yes; US DailyMed: Ranibizumab;
Pregnancy; category	AU: D ;
Routes of; administration	Intravitreal injection
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Pharmacokinetic data
Elimination half-life	Approx. 9 days
Chemical and physical data
Formula	C2158H3282N562O681S12
Molar mass	୪୮,୩୭୯.୯୭ g·mol−1
(verify)

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Ranibizumab

ରାନିବିଜୁମାବ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଲୁସେଣ୍ଟିସ ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ବୟସ ସମ୍ବନ୍ଧୀୟ ମାକୁଲାର ଡିଜେରେସନ୍ (AMD), ମଧୁମେହ ରେଟିନୋପାଥି, ରେଟିନା ଶିରା ଅବରୋଧ ଯୋଗୁ ହେଉଥିବା ମାକୁଲାର ଇଡିମା ଓ ଅକାଳର ରେଟିନୋପାଥି ରୋଗମାନଙ୍କର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୫] ଏହା ଆଖିରେ ଇଞ୍ଜେକ୍ସନ ଆକାରରେ ଦିଆଯାଏ ।^[୫]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ କଞ୍ଜଙ୍କଟାଇଭାଲ ରକ୍ତସ୍ରାବ, ଆଖି ଯନ୍ତ୍ରଣା, ଫ୍ଲୋଟର ଏବଂ ଅଧିକ ଇଣ୍ଟ୍ରାଅକୁଲାର ଚାପ ସୃଷ୍ଟି ହୋଇପାରେ ।^[୬] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଏଣ୍ଡୋଫଥାଲମାଇଟିସ ଏବଂ ନେତ୍ରପଟଳ ସ୍ଖଳନ ହୋଇପାରେ ।^[୬] ଏହା ମୋନୋକ୍ଲୋନାଲ ଆଣ୍ଟିବଡିର ଏକ ଛୋଟ ଖଣ୍ଡ ଯାହା ଭାସ୍କୁଲାର ଏଣ୍ଡୋଥେଲିଆଲ୍ ଅଭିବୃଦ୍ଧି କାରକ ଏ (VEGF-A) ସ‌ହିତ ସଂଲଗ୍ନ ହୁଏ ଏବଂ ଅବରୋଧ କରେ । ^[୫]

୨୦୦୬ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୦୭ରେ ୟୁରୋପରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ରାନିବିଜୁମାବ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୬] ^[୫] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୨୧ ସୁଦ୍ଧା ଏକ ମାତ୍ରା ପିଛା ପ୍ରାୟ ୫୫୦ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ ହୁଏ ।^[୭] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ମୂଲ୍ୟ ପ୍ରାୟ୨୦୦୦ ଡଲାର ଅଟେ ।^[୮]

ଆଧାର

1 2 "AusPAR: Ranibizumab". Therapeutic Goods Administration (TGA). 9 December 2014. Archived from the original on 21 September 2021. Retrieved 20 September 2021.
1 2 "Lucentis- ranibizumab injection, solution". DailyMed. Archived from the original on 21 September 2021. Retrieved 20 September 2021.
↑ "Lucentis EPAR". European Medicines Agency. Archived from the original on 10 September 2021. Retrieved 9 September 2021.
↑ "Byooviz EPAR". European Medicines Agency. 23 June 2021. Archived from the original on 10 September 2021. Retrieved 9 September 2021.
1 2 3 4 "Lucentis". Archived from the original on 10 September 2021. Retrieved 15 October 2021.
1 2 3 "DailyMed - LUCENTIS- ranibizumab injection, solution". dailymed.nlm.nih.gov. Archived from the original on 21 September 2021. Retrieved 15 October 2021.
↑ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1255. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
↑ "Lucentis Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 29 December 2018. Retrieved 15 October 2021.

[AusPAR:_Ranibizumab-1] 1 2 "AusPAR: Ranibizumab". Therapeutic Goods Administration (TGA). 9 December 2014. Archived from the original on 21 September 2021. Retrieved 20 September 2021.

[Lucentis_FDA_label-2] 1 2 "Lucentis- ranibizumab injection, solution". DailyMed. Archived from the original on 21 September 2021. Retrieved 20 September 2021.

[Lucentis_EPAR-3] "Lucentis EPAR". European Medicines Agency. Archived from the original on 10 September 2021. Retrieved 9 September 2021.

[Byooviz_EPAR-4] "Byooviz EPAR". European Medicines Agency. 23 June 2021. Archived from the original on 10 September 2021. Retrieved 9 September 2021.

[EPAR2021-5] 1 2 3 4 "Lucentis". Archived from the original on 10 September 2021. Retrieved 15 October 2021.

[PI2021-6] 1 2 3 "DailyMed - LUCENTIS- ranibizumab injection, solution". dailymed.nlm.nih.gov. Archived from the original on 21 September 2021. Retrieved 15 October 2021.

[BNF80-7] BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1255. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[8] "Lucentis Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 29 December 2018. Retrieved 15 October 2021.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]